A recent press release by Orcosa highlights a statement made by former U.S. President Bill Clinton to the effect that the results of a clinical trial by NYU Langone, which tested the effectiveness of CBD in managing pain, were very encouraging. Clinton, who has in the past revealed that he used cannabis in his youth, has been keenly following the progression of these CBD trials.
Orcosa is a life sciences company that is focused on modernizing the way drugs are taken through the use of its next-generation drug-delivery technology. The company supplied the CBD products used in the trial, which contained TR Processing’s CBD ingredient.
In the press release, the former president is quoted as stating that the Clinton Foundation had worked for years to decrease opioid addiction and related deaths, explaining that to succeed, nonaddictive alternatives to opioids were needed to help manage patient pain. Clinton also emphasized the importance of looking into alternatives to opioid-based painkillers, noting that he was eager to see the results of the next phase of the trials. The trial involved 99 participants aged between 18 and 75, who had undergone rotator cuff surgery. Its results show that the Oravexx CBD tablet by Orcosa substantially reduced post-op pain in comparison to the placebo, without inducing any severe side effects.
This statement is similar to prior comments made by Clinton, which referenced emerging research into CBD as an effective therapy to help manage pain. At the time, the article published with Clinton’s remarks was deleted, allegedly due to pressure from the former president’s team, before being posted again online.
Regardless, these statements are a far cry from how the former president’s administration handled efforts to legalize medical marijuana, going as far as to threaten to revoke the DEA giving licenses for physicians who recommended cannabis to patients in accordance with state law.
TR Processing also revealed that Andrea Barthwell had joined the company’s board of directors and would be leading a division committed to developing patented therapies. Barthwell, who is a former White House deputy drug czar, has been criticized by cannabis advocates over previous misleading and dismissive claims that she made about medical marijuana before proceeding to assist GW Pharmaceuticals in obtaining approval for its Sativex drug, which is cannabinoid-based.
In TR Processing’s press release, Barthwell stated that she was excited by the company’s focus on cannabinoid development and believed that pharmaceutical companies, physicians and patients were looking for effective and safe solutions to manage pain as well as for general health and well-being.
As more positive comments about different cannabinoids come from leading figures such as Clinton, public perceptions could change a lot faster among all demographic segments, and the cannabis products made by companies such as Flora Growth Corp. (NASDAQ: FLGC) will enjoy an even bigger market in the years to come.
NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Do you have questions or are you interested in working with CNW420? Ask our Editor
CNW420 is part of the InvestorBrandNetwork.